Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?

Schizophrenia Research

Volumn 102, Issue 1-3, 2008, Pages 329-336

  Sengupta, Sarojini ^a   Parrilla Escobar, Maria A ^a   Klink, Ruby ^a   Fathalli, Ferid ^a   Ying Kin Ng, ^a,b   Stip, Emmanuel ^c   Baptista, Trino ^d   Malla, Ashok ^a,b   Joober, Ridha ^a,b  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^d Universidad De Los Andes Facultad de Medicina   (Venezuela)

Author keywords

First episode psychosis; Glucose metabolism; Impaired glucose tolerance; Insulin resistance; Lipid metabolism; Schizophrenia spectrum disorder

Indexed keywords

GLUCOSE; LIPID; NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; DRUG EXPOSURE; ETHNIC DIFFERENCE; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEX RATIO; WAIST HIP RATIO;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; CONTROL GROUPS; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; PROSPECTIVE STUDIES; SCHIZOPHRENIA; TRIGLYCERIDES; WAIST-HIP RATIO;

EID: 46249133594     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.02.013     Document Type: Article

References (32)

1. 1999. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 354, 617-621.
2. Addington J., Chaves A., and Addington D. Diagnostic stability over one year in first-episode psychosis. Schizophr. Res. 86 (2006) 71-75
3. Alvarez-Jimenez M., Gonzalez-Blanch C., Vazquez-Barquero J.L., Perez-Iglesias R., Martinez-Garcia O., Perez-Pardal T., Ramirez-Bonilla M.L., and Crespo-Facorro B. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J. Clin. Psychiatry 67 (2006) 1253-1260
4. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., Navarro M.A., and San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J. Clin. Psychiatry 65 (2004) 1335-1342
5. Brown S., Birtwistle J., Roe L., and Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 29 (1999) 697-701
6. Evans S., Newton R., and Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust. N. Z. J. Psychiatry 39 (2005) 479-486
7. First M.B., Spitzer R.L., Gibbon M., and Williams J.B. Structured Clinical Interview for DSM-IV Patient Edition (SCID-I/P V and SCID-I NP Version 2.0) (1998), Biometric Research Department, New York
8. Gadde K.M., Zhang W., and Foust M.S. Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. J. Clin. Psychopharmacol. 26 (2006) 409-413
9. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., Lamberti S., D'Agostino R.B., Stroup T.S., Davis S., and Lieberman J.A. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 80 (2005) 45-53
10. Gough S., and Peveler R. Diabetes and its prevention: pragmatic solutions for people with schizophrenia. Br. J. Psychiatr., Suppl. 47 S106-11 (2004) S106-S111
11. Hennekens C.H., Hennekens A.R., Hollar D., and Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 150 (2005) 1115-1121
12. Jensen C.C., Cnop M., Hull R.L., Fujimoto W.Y., and Kahn S.E. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 51 (2002) 2170-2178
13. Kwon J.S., Choi J.S., Bahk W.M., Yoon K.C., Hyung K.C., Chul S.Y., Park B.J., and Geun O.C. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J. Clin. Psychiatry 67 (2006) 547-553
14. Mansfield E., McPherson R., and Koski K.G. Diet and waist-to-hip ratio: important predictors of lipoprotein levels in sedentary and active young men with no evidence of cardiovascular disease. J. Am. Diet. Assoc. 99 (1999) 1373-1379
15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
16. Mauri M., Castrogiovanni S., Simoncini M., Iovieno N., Miniati M., Rossi A., Dell'Agnello G., Fagiolini A., Donda P., and Cassano G.B. Effects of an educational intervention on weight gain in patients treated with antipsychotics. J. Clin. Psychopharmacol. 26 (2006) 462-466
17. Mitchell A.J., and Malone D. Physical health and schizophrenia. Curr. Opin. Psychiatry 19 (2006) 432-437
18. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry 68 Suppl 1:20-7 (2007) 20-27
19. Overall J.E., and Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 10 (1962) 799-812
20. Rahm C., and Cullberg J. Diagnostic stability over 3 years in a total group of first-episode psychosis patients. Nord. J. Psychiatry 61 (2007) 189-193
21. Ryan M.C., Collins P., and Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 160 (2003) 284-289
22. Schimmelmann B.G., Conus P., Edwards J., McGorry P.D., and Lambert M. Diagnostic stability 18 months after treatment initiation for first-episode psychosis. J. Clin. Psychiatry 66 (2005) 1239-1246
23. Schwartz J.E., Fennig S., Tanenberg-Karant M., Carlson G., Craig T., Galambos N., Lavelle J., and Bromet E.J. Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Arch. Gen. Psychiatry 57 (2000) 593-600
24. Scocco P., Longo R., and Caon F. Weight change in treatment with olanzapine and a psychoeducational approach. Eat. Behav. 7 (2006) 115-124
25. Sengupta S.M., Klink R., Stip E., Baptista T., Malla A., and Joober R. Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naive patients with psychotic disorders. Schizophr. Res. 80 (2005) 131-133
26. Spelman L.M., Walsh P.I., Sharifi N., Collins P., and Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med. 24 (2007) 481-485
27. Taylor D.M., and McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr. Scand. 101 (2000) 416-432
28. Thakore J.H., Mann J.N., Vlahos I., Martin A., and Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int. J. Obes. Relat. Metab. Disord. 26 (2002) 137-141
29. Tschoner A., Engl J., Laimer M., Kaser S., Rettenbacher M., Fleischhacker W.W., Patsch J.R., and Ebenbichler C.F. Metabolic side effects of antipsychotic medication. Int. J. Clin. Pract. 61 (2007) 1356-1370
30. van W.R., De H.M., Van E.D., Hanssens L., Wampers M., Scheen A., and Peuskens J. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J. Clin. Psychiatry 67 (2006) 1493-1500
31. Wu R.R., Zhao J.P., Jin H., Shao P., Fang M.S., Guo X.F., He Y.Q., Liu Y.J., Chen J.D., and Li L.H. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 299 (2008) 185-193
32. Zhang Z.J., Yao Z.J., Liu W., Fang Q., and Reynolds G.P. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br. J. Psychiatry 184 58-62 (2004) 58-62